Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1905-1917

  Shalinsky, David R ^a,c   Brekken, John ^a   Zou, Helen ^a   Bloom, Laura A ^a   McDermott, Charles D ^a   Zook, Scott ^a   Varki, Nissi M ^b   Appelt, Krzysztof ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c 4245 Sorrento Valley Blvd ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTOTOXIC AGENT; METALLOPROTEINASE INHIBITOR; PACLITAXEL; PRINOMASTAT;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; DOSE RESPONSE; DRUG MIXTURE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0032791421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Richardson, G. E., and Johnson, B. E. The biology of lung cancer. Semin. Oncol., 20: 105-127, 1993.
2. Kalemkerian, G. P. Biology of lung cancer. Curr. Opin. Oncol., 6: 147-155, 1994.
3. Bunn, P. A., Jr., and Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 5: 1087-1100, 1998.
4. Shepherd, F. A. Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer (Limerick), 17 (Suppl. 1): 121-136, 1997.
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
6. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer agents. BioEssays, 13: 31-36, 1991.
7. Levy, D. E., and Ezrin, A. M. Matrix metalloproteinase inhibitor drugs. In: Emerging Drugs: The Prospective for Improved Medicines, pp. 205-230. Ashley Publications Ltd., 1997.
8. Wojtowicz-Praga, S. M., Dickson, R. B., and Hawkins, M. Matrix metalloproteinase inhibitors. Invest. New Drugs, 15: 61-75, 1997.
9. Morphy, J. R., Millican, T. A., and Porter, J. R. Matrix metalloproteinase inhibitors: current status. Curr. Med. Chem., 2: 743-762, 1995.
10. Ray, J. M., and Stetler-Stevenson, W. G. Matrix metalloproteinase and malignant disease: recent developments. Exp. Opin. Invest. Drugs, 5: 323-335, 1996.
11. Brown, P. D. Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol. (Lond.), 14: 1-10, 1997.
12. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. Matrix metalloproteinase inhibitor (BB-94) (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 54: 4726-4728, 1994.
13. Chirivi, R. G., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D., and Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58: 460-464, 1994.
14. An, Z., Wang, X., Willmott, N., Chander. S. K., Tickle, S., Docherty, A. J., Mountain, A., Millican, A. T., Morphy, R., Porter, J. R., Epemolu, R. O., Kubota T., Moossa, A. R., and Hoffman, R. M. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin. Exp. Metastasis, 15: 184-195, 1997.
15. Flynn, C., Bull, C., Eberwin, D., Matherne, C., and Hibner, B. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT-116 orthotopic model. Proc. Am. Assoc. Cancer Res., 39: 2057, 1998.
16. Santos, O., McDermott, C. D., Daniels, R. G., Appelt, K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis, 15: 499-508, 1997.
17. Hua, J., and Muschel R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res., 56: 5279-5284, 1996.
18. Itoh, T., Tanioka, M., Yoshida, H., Yohsioka, T., Nishimoto, H, and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res., 58: 1048-1051, 1998.
19. Liabakk, N-B., Talbot, I., Smith, R. A., Wilkinson, K., and Balkwill, F. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) Type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1996.
20. Hamdy, F. C., Fadlon E. J., Cottam, D., Lawry, J., Thurrell, W., Silcocks, P. B., Anderson, J. B., Williams, J. L., Rees, R. C. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer, 69: 177-182, 1994.
21. Sier, C. F. M., Kubben, F. J. G. M., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R., van Krieken, J. H. J. M., Lamers, C. B. H. W., and Verspaget, H. W. Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer, 74: 413-417, 1996.
22. Brown, P. D., Bloxidge, R. E., Stuart, N. S., Gatter, K. C., and Carmichael, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 574-578, 1993.
23. Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C. D., Forsyth, P., Edwards, D., Margosiak, S., Bender, S., Truitt, G., Wood, A., Varki, N. M., and Appelt, K. Broad antitumor and antiangiogenic activities of AG3340, a potent MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci., 878: 236-270, 1999.
24. Shalinsky, D. R., Brekken, J., Zou, H., Shetty, B., Neri, A., McDermott, C. D., Bender, S., Wood, A., Varki, N., Webber, S. and Appelt, K. AG3340, a potent and selective antiangiogenic metalloproteinase inhibitor undergoing development in oncology. In: N. Clendeninn and K. Appelt (eds.), Matrix Metalloproteinase Inhibitors in Cancer Therapy: Cancer Drug Discovery and Development, Beverly Teicher Series. Humana Press, Inc., in press, 1999.
25. Shalinsky, D. R., Brekken, J., Zou, H., Kolis, S., Wood, A., Webber, S. and Appelt, K. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest. New Drugs, 16: 303-313, 1999.
26. Price, A., Shi, Q., Morris, D., Wilcox, P. M. A., Rewcastle, N. B., Shalinsky, D., Zou, H., Appelt, K., Johnston, R. N., Yong, V. W., Edwards, D. and Forsyth, P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthematrix metalloproteinase inhibitor AG3340. Clin. Cancer Res., 5: 845-854, 1999.
27. Shalinsky, D. R., Brekken, J., Zou, H., Bender, S., Zook, S., Appelt, K., Webber, S., and Varki, N. V. Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix rnetalloprotease (MMP) inhibitor, AG3340, in male nude mice. Proc. Am. Assoc. Cancer Res., 39: A4400, 1998.
28. Zhang, K. E., McDermott, C. D., Brekken, J., Vekich, S., Shalinsky, D. R., Appelt, K., Rivero, M. E., Garcia, C. R., and Freeman, W. R. Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration. Tampa, FL: Proc. New York Acad. Sci., 1998.
29. Collier, M. A., Yuen, G. J., Bansal, S. K., Kolis, S., Chew, T. G., Appelt, K., and Clendinin, N. J. A Phase I study of the matrix metalloprotease inhibitor (MMP) inhibitor, AG3340 given in single doses to healthy volunteers. Proc. Am. Assoc. Cancer Res., 38: A1491, 1997.
30. Keiner, M. J., McMorris, T. C., Estes, L., Starr, R., Sampson, K., Varki, N., and Taetle, R. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res., 15: 867-871, 1995.
31. Howard, R., Chu, H., Zeligman, B. E., Marcell, T., Bunn, P. A., McLemore, T. L., Malvin, D. W., Cowen, M. E., and Johnston, M. R. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res., 51: 3274-3280, 1991.
32. Johnston, M. R., Mullen, J. B. M., Pagura, M., Appelt, K., and Shalinsky, D. R. AG3340, a novel matrix metalloprotease (MMP) inhibitor, inhibits the growth of human large cell lung cancer tumors orthotopically implanted into the lung of athymic nude rats. Proc. Am. Assoc. Cancer Res., 39: A2060, 1998.
33. Johnston, M. R., Mullen, J. M., Pagura, M., Brekken, J., Zou, H., and Shalinsky, D. R. AG3340 and carboplatin increase survival in an orthotopic nude rat model of primary and metastatic human lung cancer. Proc. Am. Assoc. Cancer Res., 40: A1946, 1999.
34. Favaloro, E. J., Moraitis, N., Bradstock, K., and Koutts, J. Coexpression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. Br. J. Haematol., 74: 385-394, 1990.
35. Carter, W. H., Jr., Wampler, G. L., and Stablein, D. M. In: Regression Analysis of Survival Data in Cancer Chemotherapy. New York: Dekker, 1983.
36. Carter, W. H., Jr., Chinchilli, V. M., Campbell, E. D., and Wampler, G. L. Confidence interval about the response at the stationary point of a response surface, with an application to preclinical cancer therapy. Biometrics, 40: 1125-1130, 1984.
37. Gosland, M., Lum, B., Schimmelpfennig, J., Baker, J., and Doukas, M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy, 16: 16-39, 1996.
38. Toi, M., Kashitani, J., and Tominaga, T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int. J. Cancer, 55: 371-374, 1993.
39. Weidner, N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat., 36: 169-180, 1995.
40. Bevilacqua, P., Barbareschi, M., Verderio, P., Boracchi, P., Caffo, O., Palma, P., Meli, S., Weidner, N., and Gasparini, G. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma - results of a multiparametric study. Breast Cancer Res. Treat., 36: 205-217, 1995.
41. Murray, J. D., Carlson, G. W., McLaughlin, K., Pennington, M., Lynn, M., DeRose, P. B., Williams, J. K., and Cohen, C. Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am. J. Surg., 174: 523-526, 1997.
42. Weidner, N., and Folkman, J. Tumoral vascularity as a prognostic factor in cancer. In: V. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology. Philadelphia: Lipincott-Raven Press, 1997.
43. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
44. Anderson, I. C., Shipp, M. A., Docherty, A. J., and Teicher, B. A. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res., 56: 715-718, 1996.
45. Folkman, J. Fighting cancer by attacking its blood supply. Sci. Am., 275: 150-154, 1996.
46. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired resistance. Nature (Lond.), 390: 404-407, 1997.
47. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
48. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
49. Giavazzi, R., Garofalo, A., Ferri, C., Lucchini, V., Bone, E. A., Chiari, S., Brown, P. D., Nicoletti, M. I., and Taraboletti, G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res., 4: 985-992, 1998.
50. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 12: 697-715, 1996.
51. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor), 2: 93-100, 1990.
52. Teicher, B. A., Dupuis, N. P., Robinson, M. F., Emi, Y., and Goff, D. A. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res., 7: 237-243, 1995.